

**ABSTRACT TEMPLATE for Company Presentations**  
The maximum number of words for this abstract is 300 words.

**Questions for categories: Biotech/Pharma**

○ **Investment Rational**

Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures; and management strengths.

Code Pharma BV is a global pharmaceutical company, headquartered in the Netherlands, with R&D activities centered in Israel. The company aims to develop cost-effective treatments for infectious and oncological diseases by using novel peptides and bring together outstanding professionals with multidisciplinary expertise in peptides, cell cultures, clinical development, and chemistry manufacturing. Code Pharma is developing the compound Codivir, a synthetic peptide is based on a short amino acid sequence derived from the HIV-1 integrase enzyme, originally designed for HIV treatment. It was found to have also an antiviral effect on SARS-CoV-2 and other RNA viruses. Codivir is safe and effective both in preclinical and clinical studies.

○ **Business Strategy**

Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

Code Pharma received emergency approval for Codivir in several countries and is preparing for mass production that will be ready in about 7-8 months. To this aim' we are working with companies in USA, India and potentially in Italy.

○ **Core Technology**

What is the technology, its uniqueness and its value proposition?

A peptide that has an antiviral effect on several viruses (HIV, corona viruses, Influenza, etc.)

○ **Product Profile/Pipeline**

Briefly describe the company's product/pipeline, current status and market potential. Discuss milestones, potential collaborations and partnerships.

Codivir is currently being investigated under Phase2A clinical study for Covid-19.

Also, will be submitted in the near future for Phase2 in HIV patients.

**What's Next?**

R&D – Establish MOA for RNA viruses.

Preclinical / Clinicals – Phase2A clinical trial is ongoing. New trials: Phase 2 for HIV and a proof of concept clinical trial for influenza.

Organizational Plans

Financial Plans – Code Pharma is preparing an IPO in NASDAQ for 2023.